Skip to main content

Table 1 Patient Characteristics (N = 357)

From: The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer

Characteristic Patients
N (%)
Age, median (range)  
Sex  
Male 214 (60)
Female 143 (40)
ECOG performance status 0-1 326 (91)
Primary tumor location  
Gastroesophageal junction/proximal stomach 107 (30)
Mid to distal stomach 231 (65)
Unclassifiable/Unknown 19 (5)
Disease status  
Stage IV at diagnosis 298 (83)
z Recurrent disease 59 (17)
First-line chemotherapy  
3-drug combination (FLOT) 192 (54)
2-drug combination (FLO or FLP) 165 (46)
Metastatic disease sites  
Liver 157 (44)
Lymph nodes 219 (61)
Peritoneum 93 (26)
Lung 60 (17)
Lauren classification  
Diffuse/mixed 170 (48)
Intestinal 139 (39)
Other/Unknown 48 (13)
Sampling specimen  
Biopsy 238 (67)
Surgical specimen 116 (33)
Unknown 3 (1)
Primary tumor 298 (83)
Metastatic lesion 50 (14)
Unknown 9 (3)
  1. Abbreviations: FLOT, 5-FU, leucovorin, oxaliplatin and docetaxel; FLO, 5-FU, leucovorin, oxaliplatin; FLP, 5-FU, folic acid, cisplatin.
  2. 5-FU, Leucovorin and Oxaliplatin (FLO), 5-FU, Folic acid and Cisplatin (FLP).